RELIEF THERAPEUTICS Holding AG (SIX: RLF) publishes the agenda for its 2018 Annual General Meeting

08 June 2018

RELIEF THERAPEUTICS Holding AG (“Relief” or “Company”) today announces the following agenda items for the Annual General Meeting of Shareholders (“AGM”) of June 29, 2018:

1.             Approval of the Annual Report, Statutory Financial Statements (balance sheet, income statement and notes) and Consolidated Financial Statements for the year 2017, Statutory Auditors’ Report

2.             Appropriation of Results

3.             Discharge of the members of the Board of Directors and of the Executive Committee

4.             Votes on the compensation of the members of the Board of Directors and of the Executive Committee

4.1     Binding vote on the total compensation of the members of the Board of Directors for the period from the annual general meeting 2018 until the annual general meeting 2019

4.2     Binding vote on the total remuneration of the members of the Executive Committee for the financial year 2018

4.3     Consultative vote on the Compensation Report 2017

5.             Elections

5.1     Board of Directors

5.2     Chairman of the Board of Directors

5.3     Nomination and Compensation Committee

5.4     Independent Voting Rights Representative

5.5     Auditors

Formal invitations will be sent directly to the Shareholders.

The Board of directors looks forward to welcome you at their offices in avenue de Secheron 15, rooms Vesta and Orion at 14.00 on the 29th of June. Doors open at 13.30.

About Relief Therapeutics Holding AG

 RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (Phase III-ready) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (Phase II-ready). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, and has been the subject of multiple clinical trials. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.

Investor relations contact:

Tel: +41 44 723 59 59

This email address is being protected from spambots. You need JavaScript enabled to view it.


This communication expressly or implicitly contains certain forward-looking statements concerning Relief Therapeutics Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics Holding AG to be materially different from any future results,  performance or achievements expressed or implied by such forward-looking statements. Relief Therapeutics Holding AG is providing this communication as of this date and does not undertake to update any forward looking statements contained herein as a result of new information, future events or otherwise.